However, the discrepancy in hematocrit bias shows that accuracy established in one patient population cannot be automatically extrapolated to other patient populations, thus stressing the need for separate evaluation. The i-STAT analyzer is suitable for point-of-care testing of electrolytes and blood gases in critically ill patients, except for high pO2. In conclusion, this study shows that blood gas analysis using the i-STAT portable device is. Between 16 and 55 kPa (n44), there was a systematic but small (-0.69+/-0.67 kPa) underestimation of Pa,O2 measured with the i-STAT (p<10 (-8)). 0001) in the hematocrit range below 25% (n = 11) using the i-STAT. Below 15 kPa (n48), the two systems gave nearly identical values, the mean difference was 0.01+/-0.37 kPa. In contrast to hematocrit measured during CPB, hematocrit using the non-CPB mode in the non-cardiac intensive care population showed an underestimation up to 2.2% (p <. In the normal pO2 range (10.6 < pO2 < 13.3 kPa), the performance of the i-STAT was comparable to the RapidLab. 0001 when 10 < 30 kPa) and in the intensive care unit (r = -0.61,p <. A clear linear trend in deviation of i-STAT from RapidLab was noticed for pH during CPB (r = 0.32, p =. Point-of-care electrolytes and blood gases had constant deviation, except for pH, pO2, and hematocrit. The agreement analysis for quantitative data was used to compare i-STAT to RapidLab for blood gas/electrolytes and for hematocrit with the Sysmex instrument. During a 3-month period, 48 blood samples from patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) and 42 blood samples from non-cardiac patients who needed intensive care treatment were analyzed on both the i-STAT analyzer (CPB and non-CPB mode, respectively) and our laboratory analyzers (RapidLab 865/Sysmex XE-2100 instrument). We therefore evaluated the analytical performance of the i-STAT point-of-care analyzer in two critically ill adult patient populations. This is especially true when biochemical parameters exceed the clinical reference range, in which acute and effective treatment is essential. Point-of-care analyzers may benefit therapeutic decision making by reducing turn-around-time for samples.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |